Objective To investigate the effects of urinary kallidinogenase combined with butylphthalide on serum brain-derived neurotrophic factor (BDNF) and collateral circulation in patients with atherosclerotic cerebral infarction.
Methods A total of 200 patients with atherosclerotic cerebral infarction in Shijiazhuang People′s Hospital of Hebei Province were analyzed and randomly divided into observation group and control group, with 100 cases in each group. The control group was treated with butylphthalide, and the observation group was given urinary kallidinogenase combined with butylphthalide. Clinical efficacy, activities of daily living (ADL) score, ischemic hypoperfusion area, cerebral blood flow (CBF) of collateral circulation and BDNF level were compared between the two groups.
Results After treatment, the serum BDNF level, ADL score and CBF of the two groups were significantly higher than those before treatment, and the observation group was significantly higher than the control group (P < 0.05); the ischemic hypoperfusion area in the two groups was significantly smaller than before treatment, and the observation group was significantly smaller than the control group (P < 0.05); the total effective rate of the observation group was 93.00%, which was significantly higher than 83.00% of the control group (P < 0.05).
Conclusion Urinary kallidinogenase combined with butylphthalide has a significant therapeutic effect in patients with atherosclerotic cerebral infarction, which can effectively enhance the level of BDNF and living ability, improve collateral circulation, and reduce the area of ischemia-reperfusion area.
DownLoad: